Claims for Patent: 5,371,193

Summary for Patent: 5,371,193

Title:	Mammalian cytokine, IL-11
Abstract:	A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.
Inventor(s):	Bennett; Frances K. (Melrose, MA), Paul; Stephen R. (Boston, MA), Yang; Yu-Chung (Indianapolis, IN)
Assignee:	Genetics Institute, Inc. - Legal Affairs (Cambridge, MA)
Application Number:	08/017,522
Patent Claims:	1. Isolated IL-11 having IL-11 activity and comprising an amino acid sequence as set forth in SEQ ID NO: 2 or 4. 2. The protein of claim 1 which is human IL-11. 3. Isolated mature IL-11 having IL-11 activity and encoded by a DNA sequence as in SEQ ID NO: 1 or 3, or a DNA sequence capable of hybridizing thereto under stringent conditions. 4. Isolated mammalian IL-11 having one or more of the following characteristics: (1) an apparent molecular weight under reducing conditions on SDS PAGE of approximately 20 kD; (2) a calculated molecular weight of approximately 20 kD; (3) biological activity in a T1165 assay; (4) biological activity in a megakaryocyte colony forming assay in the presence of IL-3; (5) biological activity on a B cell plaque forming assay. 5. The protein of claim 3 having biological activity in the T1165 assay in the absence of IL-6. 6. The protein of claim 4 produced by: culturing a cell transformed with a DNA sequence encoding expression of an II-11 polypeptide in operative association with an expression control sequence capable of directing the replication and expression of IL-11, and recovering from the conditioned medium thereof an IL-11 protein. 7. The protein of claim 6 wherein said DNA sequence encoding said protein comprises a DNA sequence of SEQ ID NO. 1 or 3, or a DNA sequence capable of hybridizing thereto under stringent conditions. 8. A pharmaceutical composition comprising a therapeutically effective amount of the protein of claim 4 in a pharmaceutically effective vehicle.

Details for Patent 5,371,193

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694	11/25/1997		2011-12-06

International Patent Family for US Patent 5,371,193

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9107495
United States of America	6066317
United States of America	5854028
United States of America	5700664